Trial
NCT03338296
Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Eisai Inc.
Collaborators
—
Condition
Obesity
Intervention
lorcaserin hydrochloride XR
Why stopped
Study was terminated as Eisai agreed to voluntarily withdraw Belviq XR from US market.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-19